<DOC>
	<DOCNO>NCT01816295</DOCNO>
	<brief_summary>The main purpose study evaluate testosterone solution raise testosterone hormone level normal range , also improve level sexual arousal , interest drive and/or energy level , men low testosterone decrease sexual arousal , interest drive and/or decrease energy . The study last 16 week , follow optional 24 week open label treatment phase investigate long term safety testosterone solution .</brief_summary>
	<brief_title>A Study Men With Low Testosterone Measure Effects Testosterone Solution Testosterone Levels , Sex Drive Energy</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Total testosterone level &lt; 300 nanogram per deciliter ( ng/dL ) [ 10.4 nanomole per Liter ( nmol/L ) ] 2 screen visit At least 1 symptom testosterone deficiency , must include decreased energy decrease sexual drive Prostate Specific Antigen ( PSA ) &lt; 4 nanogram per milliliter ( ng/ml ) screen Sexual partner become pregnant time study Use longacting intramuscular ( IM ) testosterone undecanoate testosterone pellet 6month period prior screen Body Mass Index ( BMI ) &gt; 37 kilogram per square meter ( kg/m^2 ) screening Severe low urinary tract symptom and/or significant prostate enlargement Prolactin lab test result &gt; 30 ng/mL screen Hemoglobin A1c ( HbA1c ) &gt; 11 % screen Hematocrit ≥50 % ( &gt; 54 % elevated altitude ) screen Current use medication , herbal , and/or nutritional supplement interfere testosterone Dermatologic condition underarm area might interfere testosterone absorption ( example , eczema ) exacerbate topical testosterone replacement therapy Currently receive treatment cancer chemotherapy antiandrogens Chronic use systemic glucocorticoid ( use &gt; 14 day within 3 month prior screen ) ; use nontestosterone anabolic steroid within 12 month prior screen Competitive athlete involve sport may screen anabolic steroid History use estrogenizing agent within 12 month prior screen History luteinizing hormonereleasing hormone antagonist agonist treatment last 6 month prior screen History clomiphene antiestrogen treatment 3 month prior screen Use finasteride within 3 month prior screen , use dutasteride within 6 month prior screen Current use warfarin phenprocoumon History frequent opioid use : &gt; 1 time/week week within 30 day prior screen Current use dopamine receptor agonist ( cabergoline , pergolide , bromocriptine ) Have history significant central nervous system injury disease ( include stroke , spinal cord injury , multiple sclerosis ) within 6 month prior screen Systolic blood pressure &gt; 170 &lt; 90 millimeter mercury ( mm Hg ) diastolic blood pressure &gt; 100 &lt; 50 mm Hg screen history malignant hypertension History unstable angina define Braunwald Classification Unstable Angina angina occur sexual intercourse last 6 month History follow coronary condition within 90 day screen : myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention ( angioplasty stent placement ) Have supraventricular arrhythmia uncontrolled ventricular response [ mean heart rate &gt; 100 beat per minute ( bpm ) ] rest , history spontaneous induce sustained ventricular tachycardia ( heart rate &gt; 100 bpm ≥30 second ) , use automatic internal cardioverterdefibrillator Have history sudden cardiac arrest Exhibit evidence congestive heart failure [ New York Heart Association ( NYHA ) Class 2 ] , within 6 month prior screen Have new , significant cardiac conduction defect within 90 day prior screen Clinical suspicion ( history ) prostate cancer digital rectal examination screen Known suspect breast cancer ( history breast cancer ) active cancer ( exception nonmelanotic skin cancer ) Exhibit evidence severe renal impairment [ creatinine clearance &lt; 30 milliliter per minute ( mL/min ) determine CockcroftGault formula ] screen Exhibit history severe liver disease clinical evidence hepatic impairment screen Have history human immunodeficiency virus ( HIV ) infection Severe sleep apnea Untreated hypothyroidism , hypercortisolism significant endocrinopathy ( hypogonadism ) contribute symptom low energy fatigue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>